New study demonstrates the efficacy of a promising celiac disease drug at the molecular level

by

A recent study led by researchers at Tampere University investigated whether a transglutaminase 2 inhibitor has potential as a drug to treat celiac disease. Previous tissue studies have shown that the ZED1227 transglutaminase 2 inhibitor prevents gluten-induced intestinal damage.

Leave A Comment

Your email address will not be published. Required fields are marked *